title: Patent ductus arteriosus: wait and see?
abstract: "Patent ductus arteriosus is one of most common problems that physicians caring for preterm infants have to face. Although medical and surgical treatment of PDA has been extensively investigated, results from the randomized controlled trials and metanalysis are still inconclusive and many authors therefore suggest a less aggressive attitude toward PDA. In the present review evidence for and against routine treatment of PDA are analyzed. A strict selection of those patients who are most likely to benefit from treatment is probably an appropriate strategy at this time but further studies, mainly targeted to long term outcomes, are needed to provide definitive indications."
authors.affiliation: UO Neonatologia e TIN, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy. federico.schena@mangiagalli.it
authors.forename: Federico
authors.initials: F
authors.lastname: Schena
authors.forename: Elena
authors.initials: E
authors.lastname: Ciarmoli
authors.forename: Fabio
authors.initials: F
authors.lastname: Mosca
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D004374:Ductus Arteriosus, Patent / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007052:Ibuprofen / Q000009:adverse effects*; D007213:Indomethacin / Q000009:adverse effects*; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy / Q000503:physiopathology; D018579:Patient Selection; D057832:Watchful Waiting
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007052:Ibuprofen; D007213:Indomethacin